*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Efficacy of biological agents in stricturing Crohn’s disease: A retrospective cohort study

Author: MAHMOUD ALCHLAIHAWI, SRIHARAN SELVARATNAM, SUDARSHAN PARAMSOTHY, RUPERT LEONG
Abstract: Background: Despite the effectiveness of Endoscopic balloon dilatation (EBD) in treating intestinal stricture in Crohn’s disease, there is still a high recurrence rate which leads to high rates of re-dilatation and sometimes leads to failure of the procedure. Aims: The aim is to determine whether biological agents affect the efficacy, safety and longevity following Crohn’s disease intestinal stricture dilatation. Materials and Methods: A retrospective single-center analysis was performed of all patients who underwent EBD between 2010 and 2018 for the management of intestinal strictures due to CD. Patients were analyzed according to whether they received concurrent treatment with biological agents at the time of EBD or not. Short-term efficacy was defined by the initial technical success rate, whilst long-term efficacy was defined by cumulative surgery-free and re-dilatation-free survival rates. Results: Twenty-eight consecutive subjects were recruited comprising of 13 with anastomotic stricture (AS, 13 strictures) and 15 with primary stricture (PS, 21 strictures). There was no difference between the AS and PS cohorts in patients’ demographics and disease characteristics apart from non-statistically significant difference in the presence of fistulas and need for surgery. EBD initial technical success rate was significantly higher for PS (98%) versus AS (70%, p = 0.037). The use of biological agents did not influence either the re-dilatation or surgery-free survival in either AS (HR: 2.07, 95%CI: 0.41–10.36, p = 0.38) or PS (HR: 0.55, 95%CI: 0.11–2.68, p = 0.46) cohorts. Conclusions: EBD is effective and safe. Biological agents did not improve re-dilatation and surgery free survival.
Keyword: Crohn’s disease; intestinal stricture; biological agents; endoscopic balloon dilatation; complications
DOI: https://doi.org/10.31838/ijpr/2020.12.04.629
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free